- 210
- 471 643
KDIGO
Приєднався 29 вер 2017
Hiding in Plain Sight: The Utility of Genetic Testing in Common Forms of CKD
CME Info:
- Full CME details: kdigo.co/Module-2-Genetics-CKD-CME-Info
- After watching the content video, complete the CME posttest & evaluation: www.surveymonkey.com/r/V83Q5Q7
- Earn 1.0 CME credit
"Hiding in Plain Sight: The Utility of Genetic Testing in Common Forms of CKD" is the second webinar in KDIGO's four-part webinar series on genetic testing for CKD. In this webinar, Professors Andrew Mallett, MD (Australia), Emilie Cornec-Le Gall, MD (France), Judy Savige, MD (Australia), and Katalin Susztac, MD (United States) discuss the utility of genetic testing in common forms of CKD. The webinar also examines the role of genetic testing when diagnosing cystic kidney disease, glomerular disease, and APOL1 kidney disease.
For additional webinar series information, please visit: kdigo.co/Genetic-Testing-for-CKD-Web-Series
The webinar took place on December 4, 2024. This webinar was supported by an educational grant from Natera. This activity is jointly provided by Global Education Group and KDIGO.
- Full CME details: kdigo.co/Module-2-Genetics-CKD-CME-Info
- After watching the content video, complete the CME posttest & evaluation: www.surveymonkey.com/r/V83Q5Q7
- Earn 1.0 CME credit
"Hiding in Plain Sight: The Utility of Genetic Testing in Common Forms of CKD" is the second webinar in KDIGO's four-part webinar series on genetic testing for CKD. In this webinar, Professors Andrew Mallett, MD (Australia), Emilie Cornec-Le Gall, MD (France), Judy Savige, MD (Australia), and Katalin Susztac, MD (United States) discuss the utility of genetic testing in common forms of CKD. The webinar also examines the role of genetic testing when diagnosing cystic kidney disease, glomerular disease, and APOL1 kidney disease.
For additional webinar series information, please visit: kdigo.co/Genetic-Testing-for-CKD-Web-Series
The webinar took place on December 4, 2024. This webinar was supported by an educational grant from Natera. This activity is jointly provided by Global Education Group and KDIGO.
Переглядів: 215
Відео
ISN-KDIGO Webinar: KDIGO Workshop on the Nurse’s Role in Managing Symptoms of People on Dialysis
Переглядів 30614 днів тому
Nephrology nurses have a pivotal role in the multidisciplinary assessment and management of symptoms experienced by people receiving dialysis. In December 2023, KDIGO held a workshop to collaboratively develop and recommend processes for articulating the important role of nurses in capturing and managing dialysis-associated symptoms. This webinar will discuss the symptoms patients on dialysis e...
Updates in IgA Nephropathy - Part 2 with Dr. Jürgen Floege
Переглядів 597Місяць тому
In this informative video, Jürgen Floege, MD (Germany) delves into the latest updates in IgA Nephropathy (IgAN), highlighting advancements in treatment strategies, emerging therapies, the role of prediction tools in disease prognosis, and the practical integration of research into clinical care. Dr. Floege addresses the challenges of global implementation, emphasizing how resource and cost cons...
Updates in IgA Nephropathy - Part 1 with Dr. Brad Rovin
Переглядів 794Місяць тому
In this insightful video, Brad Rovin, MD (United States) discusses the latest updates in IgA nephropathy, focusing on advances in diagnosis, treatment, and patient care. Dr. Rovin highlights the evolving role of novel therapies, biomarkers, and patient-centered approaches in managing this complex kidney disease. Dr. Rovin's expert perspective offers invaluable guidance for clinicians navigating...
Module 1 - Implementing Genetic Testing for CKD Webinar Series
Переглядів 671Місяць тому
In Module 1 of KDIGO's four-part webinar series, "Foundational Principles in the Role of Genetics for CKD Management," Professors Andrew Mallett, MD (Australia), Hila Rasouly, MD (United States), and Ali Gharavi, MD (United States) discuss key messages from KDIGO Guidelines on the prevalence of genetic causes of CKD and foundational principles in the role of genetics for CKD management. This we...
KDIGO 2024 CKD Guidelines Unpacked: Hear it Straight from the Experts
Переглядів 2,7 тис.4 місяці тому
This webcast, moderated by Vivek Jha, MD (India), and featuring presentations by Edgar V. Lerma, MD (United States) and Giorgina Piccoli, MD (Italy), addresses the implications of the 2024 KDIGO CKD Guideline and ways to delay the progression of CKD. The webcast was originally recorded on July 23, 2024.
IPNA-ISN-KDIGO Webinar - Contemporary Management of SSNS and SRNS: Latest Guidance from IPNA & KDIGO
Переглядів 1,2 тис.4 місяці тому
This webinar is designed to enhance the knowledge and clinical skills of healthcare professionals in managing steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS). Viewers will gain a thorough understanding of the guideline recommendations from the ISN, IPNA, and KDIGO. The session delves into the interpretation and practical application of these guideline...
APOL1 Controversies Conference Plenary Presentation: APOL1 Diagnostics and Therapeutics
Переглядів 3425 місяців тому
This is a recording of the plenary presentation, "APOL1 Diagnostics and Therapeutics," by Dr. Kirk Campbell (United States) from the KDIGO Controversies Conference on APOL1 Kidney Disease. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, includ...
APOL1 Controversies Conference Plenary: Patient & Caregiver Panel Discussion
Переглядів 1155 місяців тому
This is a recording of the Patient & Caregiver Panel Discussion from the KDIGO Controversies Conference on APOL1 Kidney Disease. The discussion took place during the conference plenary presentations. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakehold...
APOL1 Controversies Conference Plenary: Ethics of Genetic Testing
Переглядів 1255 місяців тому
This is a recording of the plenary presentation, "Ethics of Genetic Testing," by Dr. Rulan Parekh (Canada) from the KDIGO Controversies Conference on APOL1 Kidney Disease. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, including patients, car...
APOL1 Controversies Conference Plenary: Epidemiology of APOL1 Kidney Disease
Переглядів 2575 місяців тому
This is a recording of the plenary presentation, "Epidemiology of APOL1 Kidney Disease," by Dr. Sarala Naicker (South Africa) from the KDIGO Controversies Conference on APOL1 Kidney Disease. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, incl...
APOL1 Controversies Conference Plenary: APOL1 Pathophysiology
Переглядів 3585 місяців тому
This is a recording of the plenary presentation "APOL1 Pathophysiology" by Dr. David Friedman (United States) from the KDIGO Controversies Conference on APOL1 Kidney Disease. Dr. Akinlolu Ojo (United States) and Dr. Ifeoma Ulasi (Nigeria) co-chaired this conference in Accra, Ghana, in April 2024. The conference brought together key thought leaders and relevant stakeholders, including patients, ...
Personalizing Our Approach: A Focus on Managing the Non-diabetic Patient in CKD
Переглядів 1,1 тис.5 місяців тому
This is the fifth webinar in a five-part series on the holistic approach to evaluating and managing chronic kidney disease (CKD) based on the KDIGO 2024 CKD Guideline. In this webinar, KDIGO CKD Guideline Work Group Members Rasheeda Hall, MD (United States) and William Herrington, MD (United Kingdom) guide attendees through an interactive case study to show the step-wise approach to managing pa...
KDIGO 2024 Guideline on Lupus Nephritis (LN): A Roundtable Discussion
Переглядів 5 тис.6 місяців тому
This is a recording of the session "KDIGO 2024 Guideline on Lupus Nephritis (LN): A Roundtable Discussion" from the 2024 ERA Congress in Stockholm, Sweden. The session was co-chaired by KDIGO LN Guideline Co-Chair Brad Rovin, MD (United States) and LN Guideline Work Group Member Vladimir Tesar, MD (Czechia), with presentations by LN Guideline Work Group Members Juan Manuel Mejía Vilet, MD (Mexi...
KDIGO Scientific Symposium on the Impact of Viral Infection and the Role of Vaccines in Kidney Care
Переглядів 7186 місяців тому
This is a recording of the KDIGO scientific symposium, "The Impact of Viral Infections in Patients with Renal Diseases and the Role of Vaccination in Kidney Care," which was held at the 61st ERA Congress in Stockholm, Sweden, in May 2024. The symposium was chaired by Steven Chadban, MD (Australia), with speakers Uyen Huynh-Do, MD (China), Michel Jadoul, MD (Belgium), and Deepali Kumar, MD (Cana...
KDIGO Heart Failure & Kidney Disease Conference Plenary: Patient Panel
Переглядів 3786 місяців тому
KDIGO Heart Failure & Kidney Disease Conference Plenary: Patient Panel
KDIGO Heart Failure & CKD Conference Plenary: Prediction of Heart Failure in Patients with CKD
Переглядів 5196 місяців тому
KDIGO Heart Failure & CKD Conference Plenary: Prediction of Heart Failure in Patients with CKD
KDIGO Heart Failure & Kidney Disease Conference Plenary: Interdisciplinary Care Models
Переглядів 2916 місяців тому
KDIGO Heart Failure & Kidney Disease Conference Plenary: Interdisciplinary Care Models
KDIGO Heart Failure & Kidney Disease Conference Plenary: A New Era of GDMT
Переглядів 1,6 тис.6 місяців тому
KDIGO Heart Failure & Kidney Disease Conference Plenary: A New Era of GDMT
KDIGO Heart Failure & Kidney Disease Conference Plenary: New AHA CKM Staging
Переглядів 7296 місяців тому
KDIGO Heart Failure & Kidney Disease Conference Plenary: New AHA CKM Staging
KDIGO 2024 Guideline for Chronic Kidney Disease: Key Messages for Primary Care Physicians
Переглядів 1,8 тис.6 місяців тому
KDIGO 2024 Guideline for Chronic Kidney Disease: Key Messages for Primary Care Physicians
KDIGO 2024 ANCA Vasculitis Guideline: Reading Between the Lines
Переглядів 2,6 тис.6 місяців тому
KDIGO 2024 ANCA Vasculitis Guideline: Reading Between the Lines
61st ERA Congress Highlights on Complement-Mediated Kidney Disease with Marina Vivarelli
Переглядів 5946 місяців тому
61st ERA Congress Highlights on Complement-Mediated Kidney Disease with Marina Vivarelli
61st ERA Congress Highlights on IgA Nephropathy with Jonathan Barratt
Переглядів 1,3 тис.6 місяців тому
61st ERA Congress Highlights on IgA Nephropathy with Jonathan Barratt
A Contemporary Approach to Treatment of Anemia for Dialysis Patients: A KDIGO Perspective
Переглядів 1,5 тис.7 місяців тому
A Contemporary Approach to Treatment of Anemia for Dialysis Patients: A KDIGO Perspective
Expert Roundtable Discussion on Dialysis-Related Amyloidosis (DRA)
Переглядів 4677 місяців тому
Expert Roundtable Discussion on Dialysis-Related Amyloidosis (DRA)
Dialysis-Related Amyloidosis (DRA): We Still Have a Long Way to Go
Переглядів 3427 місяців тому
Dialysis-Related Amyloidosis (DRA): We Still Have a Long Way to Go
Dialysis-Related Amyloidosis: A Perspective from the US
Переглядів 4227 місяців тому
Dialysis-Related Amyloidosis: A Perspective from the US
Pathophysiology of Dialysis-Related Amyloidosis: B2-Microglobulin-Related Amyloid Fibril Formation
Переглядів 5167 місяців тому
Pathophysiology of Dialysis-Related Amyloidosis: B2-Microglobulin-Related Amyloid Fibril Formation
KDIGO 2024 Guideline on ANCA-Associated Vasculitis: Update on Current Management and Treatment
Переглядів 6 тис.7 місяців тому
KDIGO 2024 Guideline on ANCA-Associated Vasculitis: Update on Current Management and Treatment
This was an amazing talk. I really enjoyed it. Thank you.
Hi i am Pranay Kumar from india i get diagnosed with iga nephropathy and 80 % kidney damaged. Please let me know what am i supposed to do .
Thank you for sharing and empowering physician all around the world.
After one year of treatment with cortisone and farxiga my proteinuria is still the same and incurable
Though wayyy more accurate, Cystatin C is also very expensive in my (3rd world) country 😭 hence I personally choose to reserve it to patients who can afford it, or those with wonky muscle mass
❤
Thank you, for this information My 29 year daughter college undergrad was in the hospital for kidneys failure about 3 weeks ago, and now she needs a kidney transplant but she was also diagnosed with Anca/Vasculitis.
TERRIFIC information in a nutshell
Great session!
Koch Cove
Brown Glen
Durgan Common
I was diagnosed with C3GN at age 9 in 2014. Since then I've had renal biopsy procedures, been on steriods, immunosuppressive drugs, ACE inhibitors and so much more. I had nephrotic range proteinuria for 8 years and 2 years ago my proteinuria fell below the nephrotic range and entered sub-nephrotic range proteinuria. When I was given cyclosporin, I had a huge reaction to it and became severely hypertensive, had PRES syndrome and ended up in a coma. I'm hopeful as the research of this rare condition gets further, they can find treatments and cures for these complicated diseases.
Hauck Manors
Deshawn Ridge
I was diagnosed with C3GN at age 9 in 2014. At that time they diagnosed it as MPGN type 1, but after reclassification, my doctor confirmed it as C3GN. Have had so many treatments, tests, biopsies, taken part in research trial, but Im glad to see that research is started to get us further in treatments for these rare diseases.
Camilla Mountain
Hoppe Locks
Clarabelle Forges
Such a helpful and easy to understand discussion. Thank you so much Dr. Lerma, proud to see a Filipino role model. Hoping to learn more and become a better physician as I embark on my nephro fellowship this yr! 😊
Hoeger Ville
Clovis Fort
Jacobi Vista
Informative
Thank you
Thank you all
❤
❤
🙏
Anderson Carol Moore Maria White Donald
Taylor Sandra Hernandez Cynthia Walker Kenneth
Taylor Elizabeth Rodriguez Christopher Johnson Jose
Very Informative. We Can also use Mutrakrichantak churan of Planet Ayurveda, its a magic herb I must say.
I got IGA from covid infection!
How are you now
Nothing new here to report, folks.
What an excellent video /summary. Great job 👏🏼
Dr Tangri - one comment (constructive criticism if I may) I looked at the guidelines and they make a note that nuclear imaging is not as reliable as something like iohexol. Maybe I’m missing something?
Dr Tangri is an excellent teacher. I’m glad you were part of this panel.
Amazing presentation. I really like the panel style. Keeps it interactive.
how to pronounce this word?
Thanks
crie um projeto react com java script, contendo os seguintes itens: crie um componente react que renderize um botão com o texto: “Clique aqui” crie um componente react que renderize uma lista de números. a Lista deve ser atualizada quando o usuário clicar no botão na questão anterior crie um componente react que renderize um formulário de login. O formulário deve ter os campos e-mail e senha. crie um roteamento que inclua pelo menos duas páginas diferentes sendo uma delas: um texto informativo com alguns parágrafos sobre a importância dos softwares nos dias atuais e a outra um texto informativo sobre negócios. integre o framework bootstrap com a aplicação react. todos os elementos devem ter o seu estilo modificado pelo framework implemente uma rota de navegação autenticada em react. ou seja, crie um fluxo em que o usuário só pode acessar determinada rota se estiver autenticado. as credenciais do usuário obtidas pelo formulário de login podem ser verificadas diretamente com strings pré-definidas no código como email = “admin” e senha igual a “1234” para autenticar o usuário. as interfaces devem seguir heurísticas de ux design e ui design para ficarem melhores
Hello. Why CKD G1 is >90 and have no an upper limit? When there is hyperfiltration?
I'm a dialysis patient in the US. I take fish oils every morning before dialysis instead of using heparin as a blood thinner. The one day I forgot to take my fish oil, the dialysis machine clotted up. Fish oil does work for me.
Certainly! Based on the video transcript, here are the chapters for the video: **Chapter 1: Introduction to IGA Nephropathy and FSGS Webinar** [00:00:05][^1^][1] - Greetings and welcome - Overview of the webinar series - Introduction of speakers **Chapter 2: Diagnosing IGA Nephropathy** [00:01:17][^2^][2] - Pathology basis for diagnosis - Characteristics of IGA Nephropathy - Differential diagnosis and distinguishing factors **Chapter 3: Pathophysiology and Clinical Aspects of IGA Nephropathy** [00:13:22][^3^][3] - Historical perspective of IGA Nephropathy - Clinical trials and targeting pathways - Importance of blood pressure control and lifestyle modifications **Chapter 4: Biopsy Predictors and Stratification** [00:07:24][^4^][4] - The role of renal biopsy in diagnosis and prognosis - International consensus on classification - The Oxford approach to classification **Chapter 5: Clinical Implications of Biopsy Findings** [00:42:42][^5^][5] - The significance of crescents in IGA Nephropathy - The importance of clinical context in treatment decisions **Chapter 6: Lifestyle Modifications and Patient Management** [00:32:23][^6^][6] - Supportive therapy approaches - The impact of diet, obesity, and smoking on IGA Nephropathy - Recommendations for physical activity **Chapter 7: Conclusion and Q&A Session** [00:47:13][^7^][7] - Summary of key points from the webinar - Audience questions and expert responses - Closing remarks and future webinars These chapters provide a structured overview of the video's content, making it easier to navigate through the different topics discussed. If you need more detailed information or specific time stamps for each chapter, feel free to ask!
What is MRST classification?
thank you so much for your lecture
My protein 24 hour is over 1000. As long as I take cortisol it stays the same but whenever I stop it startd going over 1000. This proves that cortisols are just like painkillers and do not treat IGA and second IGA has no treatment and medical sciences are all defeated by it
Whats GDMT
Guideline-Directed Medical Therapy
Wonderful discussion...